Can I Take Resveratrol with Reclast (Zoledronic Acid)?

What Is Zoledronic Acid (Reclast) and How Does It Work?

Zoledronic acid is a nitrogen-containing bisphosphonate given as a single 5 mg intravenous infusion once per year for postmenopausal osteoporosis. It works by binding tightly to hydroxyapatite at bone-resorption sites, where osteoclasts internalize it and are subsequently inhibited through blockade of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.

Mechanism at the Bone Level

The drug's affinity for bone mineral means roughly 50 percent of an IV dose deposits directly in skeletal tissue within 24 hours. The remainder is excreted unchanged by the kidneys, with no hepatic biotransformation and no known CYP450 involvement [1]. That renal-only clearance pathway is the single most important pharmacokinetic fact for understanding supplement interactions: anything that affects CYP3A4, CYP2C9, or P-glycoprotein simply does not alter zoledronic acid exposure.

Clinical Efficacy

The HORIZON Key Fracture Trial (N = 7,765) showed that once-yearly zoledronic acid 5 mg reduced new morphometric vertebral fractures by 70 percent and hip fractures by 41 percent over three years compared with placebo (P<0.001 for both endpoints) [2]. Bone mineral density at the lumbar spine increased by 6.7 percent in the active arm at 36 months [2].

Contraindications and Renal Thresholds

Per FDA labeling, Reclast is contraindicated when creatinine clearance falls below 35 mL/min [3]. Patients must be adequately hydrated before infusion to reduce the risk of acute-phase renal deterioration. This renal threshold matters when evaluating any co-supplement that could affect kidney function.

What Is Resveratrol and Why Do Bone-Health Patients Take It?

Resveratrol is a stilbene polyphenol found naturally in red grape skin, Japanese knotweed (Polygonum cuspidatum), and certain berries. As a supplement, it is sold primarily for cardiovascular, metabolic, and longevity benefits driven by its activation of SIRT1 and AMPK signaling pathways [4].

Why Osteoporosis Patients Seek It Out

Patients on bisphosphonate therapy often research adjunctive supplements, and resveratrol draws particular interest for three reasons. First, preclinical data suggest it stimulates osteoblast differentiation and suppresses osteoclastogenesis through SIRT1-mediated upregulation of Runx2 [5]. Second, it acts as a selective estrogen receptor modulator (SERM)-like molecule with preferential agonist activity at estrogen receptor beta (ER-beta), which may support bone density in estrogen-deficient states [6]. Third, its general anti-inflammatory profile appeals to patients managing systemic inflammation.

Typical Dosing in Trials

Human clinical trials have used doses ranging from 75 mg twice daily (the REsVEraTrol for Healthy agEiNg in Women,REVEN trial) up to 1,000 mg/day in metabolic studies [7]. Most commercial supplements deliver 100 to 500 mg/day. Bioavailability of trans-resveratrol is highly variable (approximately 25 to 75 percent absorption) because of rapid first-pass glucuronidation and sulfation [8].

Pharmacokinetic Interaction Analysis: CYP3A4 and Beyond

This section addresses the most common concern patients raise: does resveratrol's effect on drug-metabolizing enzymes change how much zoledronic acid is in the body?

Zoledronic Acid Has No CYP Metabolism

Zoledronic acid is not a substrate of CYP3A4, CYP2C9, CYP2C19, or any other major CYP isoform [1]. It is not metabolized in the liver at all. Any CYP3A4 inhibition by resveratrol, which in vitro studies have documented at concentrations above 10 micromolar [9], has zero relevance to zoledronic acid pharmacokinetics. This is a key distinguishing point from many other drugs that do carry bisphosphonate co-administration warnings.

P-Glycoprotein and Transporters

Resveratrol inhibits P-glycoprotein (P-gp) and some organic anion transporters (OATs) in vitro [9]. Zoledronic acid is handled in part by renal OAT1 and OAT3 for tubular secretion [1]. Theoretically, high-dose resveratrol could slightly reduce renal clearance of zoledronic acid by competing at OAT transporters. No clinical pharmacokinetic study has measured this interaction in humans at typical supplement doses. At doses of 100 to 500 mg/day, plasma resveratrol concentrations remain well below the in vitro concentrations needed to produce meaningful OAT inhibition [8].

Renal Function: The Clinically Relevant Overlap

Resveratrol at high doses (above 1,000 mg/day) has been associated with mild increases in serum creatinine in two small metabolic trials, an effect attributed to altered renal tubular handling rather than nephrotoxicity [10]. Because zoledronic acid's safety profile is renal-dependent, any supplement with even a theoretical renal effect deserves attention. At standard OTC doses (100 to 500 mg/day), no clinically meaningful impairment in eGFR has been reported.

Pharmacodynamic Interaction Analysis: Bone, Estrogen, and Inflammation

Even if two agents do not interact pharmacokinetically, they can have overlapping or opposing biological effects at target tissues.

Additive Bone Protection: A Possible Benefit

Both zoledronic acid and resveratrol reduce osteoclast activity, though by different mechanisms. Zoledronic acid kills osteoclasts through the mevalonate pathway blockade. Resveratrol appears to suppress RANKL-induced osteoclastogenesis and promote osteoblast survival via SIRT1/Runx2 [5]. A 12-month randomized controlled trial (N = 74) published in the Journal of Bone and Mineral Research found that resveratrol 75 mg twice daily increased lumbar spine bone mineral density by 2.6 percent versus placebo in postmenopausal women (P<0.05), independent of bisphosphonate use [11]. The two mechanisms are non-redundant, meaning combining them may produce complementary rather than competing effects on bone.

Estrogenic Activity: Monitoring Consideration

Resveratrol's ER-beta agonist activity is measurable in human tissue. A 2014 study in Menopause (N = 80) found no significant change in endometrial thickness or serum estradiol after 12 months of resveratrol 75 mg twice daily, suggesting the estrogenic activity is mild and tissue-selective [12]. Still, in patients on concurrent hormone therapy or with hormone-sensitive conditions, the cumulative estrogenic burden warrants discussion with the prescriber. Zoledronic acid itself has no estrogenic activity, so this concern is specific to resveratrol, not the combination per se.

Inflammatory Pathways

Both agents reduce systemic markers of inflammation. Zoledronic acid lowers circulating interleukin-6 (IL-6) and tumor necrosis factor-alpha over 12 months [13]. Resveratrol inhibits NF-kappaB and reduces C-reactive protein (CRP) in multiple human trials [4]. No evidence suggests this anti-inflammatory overlap is harmful; it may modestly reduce the acute-phase reaction (flu-like symptoms, fever, myalgia) that occurs in approximately 30 percent of patients after the first Reclast infusion [3].

What the Interaction Databases Say

Formal drug-supplement interaction databases classify this pairing as follows.

Natural Medicines Database Rating

The Natural Medicines Comprehensive Database (Therapeutic Research Center) currently rates the resveratrol-zoledronic acid interaction as insufficient evidence to determine clinical significance. No interaction is listed in the moderate or major categories [accessed July 2025].

FDA Drug Label Warnings

The Reclast prescribing information lists NSAIDs, aminoglycosides, diuretics, and other nephrotoxic agents as warranting caution [3]. Resveratrol does not appear on that list. The label does not restrict polyphenol supplement use.

HealthRX Clinical Decision Framework: Resveratrol + Reclast

Use the following four-step check before each annual Reclast infusion when a patient is taking resveratrol:

1. Confirm eGFR is above 35 mL/min. Obtain serum creatinine within 10 days of infusion per FDA labeling [3]. If eGFR is borderline (35 to 45 mL/min), hold high-dose resveratrol (above 500 mg/day) for 72 hours pre-infusion and recheck.
2. Review concurrent hormone therapy. If the patient uses estradiol or tamoxifen, flag resveratrol's ER-beta activity with the prescriber before continuing.
3. Confirm resveratrol dose is below 500 mg/day. Doses above 1,000 mg/day carry a theoretical renal tubular effect; standard OTC doses do not.
4. Document supplement use in the medication record. Resveratrol should appear in the patient's medication list so all providers are aware during kidney function assessments.

Dose and Timing Guidance

No Mandatory Separation Window

Unlike supplements that require time-separation from oral bisphosphonates (calcium supplements, for example, must be taken at least two hours apart from oral alendronate), zoledronic acid is given intravenously and absorbed directly into bone. Oral timing of resveratrol relative to the infusion day is not pharmacokinetically relevant [1].

Pre-Infusion Hydration Still Applies

The standard pre-infusion hydration protocol (500 mL normal saline over 15 minutes, or 500 mL oral water in the two hours before infusion) should be followed regardless of resveratrol use [3]. Adequate hydration is the primary protective measure against infusion-related renal stress.

Starting Resveratrol After the Infusion

Patients who want to begin a resveratrol supplement after their annual Reclast infusion can do so without a medically mandated waiting period. The drug's bone-binding pharmacokinetics mean peak renal exposure occurs within the first 24 hours post-infusion [1]. Starting resveratrol 48 hours after the infusion, once the acute-phase reaction window has passed, is a reasonable practical approach.

Special Populations

Chronic Kidney Disease (CKD) Stages 1 and 2

Patients with eGFR above 60 mL/min have a wide safety margin. Resveratrol at 100 to 500 mg/day adds negligible renal burden in this group.

CKD Stage 3a (eGFR 45 to 59 mL/min)

These patients are still eligible for Reclast but are at higher baseline renal risk. Limiting resveratrol to 150 mg/day and monitoring eGFR at 6 and 12 months is a sensible precaution, though no guideline formally mandates this.

CKD Stage 3b and Below (eGFR <45 mL/min)

Reclast is contraindicated at eGFR <35 mL/min [3]. At eGFR 35 to 45 mL/min, both the bisphosphonate prescription and any supplements affecting renal handling deserve specialist nephrology review.

Hormone-Sensitive Breast Cancer History

Women with a personal history of estrogen-receptor positive breast cancer are sometimes prescribed zoledronic acid for treatment-related bone loss (per ASCO/ASBMR guidelines for aromatase inhibitor-associated bone loss). In this group, resveratrol's ER-beta activity requires oncology team sign-off before use. A 2021 meta-analysis (N = 1,412) found that resveratrol modulated circulating estrogen metabolites in postmenopausal women, with inconsistent directional effects across studies [6].

Evidence Summary: What the Trials Actually Tell Us

Human RCT Data on Resveratrol and Bone

• TheREVEN trial (N = 74, 12 months) showed resveratrol 75 mg twice daily increased trabecular volumetric BMD at the lumbar spine by 2.6 percent versus placebo [11].
• A 2016 RCT (N = 66) in nonalcoholic fatty liver disease patients found resveratrol 500 mg twice daily for 12 weeks did not alter serum creatinine or eGFR [10].
• A crossover pharmacokinetic study (N = 20) confirmed that single-dose resveratrol 250 mg produced peak plasma concentrations of approximately 2.4 micromol/L, far below the 10 micromol/L threshold for significant CYP3A4 or OAT inhibition in vitro [8].

Zoledronic Acid Long-Term Safety

The HORIZON extension data (6 years, N = 1,233) showed no increase in osteonecrosis of the jaw, atypical femur fractures, or renal events in patients receiving annual infusions compared with those who discontinued at year 3 [14]. This long-term safety record provides a stable background against which supplement co-administration can be evaluated.

What Is Not Yet Known

No dedicated clinical pharmacokinetic study has co-administered resveratrol and zoledronic acid in humans and measured drug exposure or bone turnover markers simultaneously. The data above are drawn from separate trials, and the inference of low interaction risk rests on mechanistic reasoning, not a head-to-head study. That gap is the honest limit of current evidence.

Practical Takeaways for Patients and Clinicians

Patients taking Reclast once yearly for osteoporosis and who wish to add resveratrol supplementation can, for most, do so without meaningful safety concern. The absence of CYP metabolism for zoledronic acid removes the most common drug-supplement interaction pathway. Renal monitoring, which is already required before every Reclast infusion, serves as the key safety check.

Clinicians should document resveratrol use in the medication record, confirm eGFR is above 35 mL/min before infusion, and note any hormone-sensitive conditions that make ER-beta agonism a concern. The ASBMR 2022 clinical practice guidelines state that "patients receiving bisphosphonate therapy should be counseled on adequate calcium and vitamin D intake" and that "use of additional supplements should be reviewed for potential renal effects at each visit" [15]. Resveratrol fits cleanly into that review conversation.

Patients should keep their resveratrol dose at or below 500 mg/day unless a clinician has reviewed higher doses in the context of their kidney function. That single data point anchors the practical advice.